Summit Therapeutics  

Miami,  FL 
United States
https://www.smmttx.com
  • Booth: 36145

 Products

  • Ivonescimab Anti- PD-1/ Anti-VEGF Molecule
    Summit’s compound, ivonescimab, is an investigational therapy not approved by any regulatory authority other than China’s NMPA. Ivonescimab is a potential first-in-class bispecific antibody combining the effects of immunotherapy via anti-PD-1 with anti-angiogenesis effects of anti-VEGF in a single molecule. Ivonescimab displays cooperative binding to these targets with increased avidity in the tumor microenvironment. Summit’s Phase III NSCLC trials: HARMONi/NCT6396065,  HARMONi-3/NCT05899608,  HARMONi-7/NCT06767514.  
     ...

Categories

Cancer Types
  • Lung Cancer
  • Metastatic Disease
    • Categories:
  • Antibodies
  • Biotechnology
  • Clinical Trials
  • Immunotherapy
  • Pharmaceutical
    • Loading ...

    :
    :


    Legend
    Available Timeslot
    Scheduled Appointment
    Personal Appointments
    Request
    Blocked Timeslot
    Restricted Timeslot
    Cancelled
    Declined